The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

被引:4
|
作者
Jirapinyo, Pichamol [1 ,2 ,5 ]
Thompson, Christopher C. [1 ,2 ]
Garcia-Tsao, Guadalupe [3 ,4 ]
Zucker, Stephen D. [1 ,2 ]
Ryou, Marvin [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Yale Sch Med, Sect Digest Dis, New Haven, CT USA
[4] VA CT Healthcare Syst, Sect Digest Dis, West Haven, CT USA
[5] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA
关键词
LIFE-STYLE; CIRRHOSIS; FIBROSIS; OBESITY;
D O I
10.1055/a-2146-8857
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The goals of therapy for patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease include weight loss and reduction of the portosystemic pressure gradient (PPG) to decrease the risk of hepatic decompensation. Endoscopic gastric plication (EGP) is an effective endoscopic weight loss procedure. This study aimed to assess the effect of EGP on PPG. Methods In this prospective pilot study, patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease underwent endoscopic ultrasoundguided PPGmeasurement prior to and at 6months following EGP. Primary outcomes were the change in PPG and proportion of patients experiencing . 20% reduction in PPG at 6 months. Secondary outcomes included percent total weight loss (TWL) and changes in noninvasive tests of fibrosis. Results 20 patients were included. Baseline median body mass index and liver stiffness measurement were 40.2 kg/ m2 (range 30.1.56.7) and 14.7 kPa (range 8.2.36), respectively. At 6 months, median PPG decreased from 5.4mmHg (range 0.7.19.6) to 1.8mmHg (range 0.4.17.6) (P = 0.002), with 79% (11/14) experiencing . 20% reduction. Patients experienced 12.5% (6.5%.26.1%) TWL (P < 0.001) at 6 months, with 89% (17/19) achieving . 7% and 68% (13/19) achieving . 10% TWL. There were significant improvements in noninvasive tests of fibrosis. Conclusion EGP appeared to be effective at reducing PPG in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. © 2022 Georg Thieme Verlag. All rights reserved.
引用
收藏
页码:125 / 130
页数:6
相关论文
共 50 条
  • [41] Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease
    Pons, Monica
    Simon-Talero, Macarena
    Millan, Laura
    Ventura-Cots, Meritxell
    Santos, Begona
    Augustin, Salvador
    Genesca, Joan
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (10) : 1214 - 1219
  • [42] Crohn’s Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
    Manik Aggarwal
    Rajat Garg
    Gopanandan Parthasarthy
    Amy S. Nowacki
    Ruthvik Padival
    Arthur McCullough
    Taha Qazi
    Benjamin Click
    Florian Rieder
    Benjamin L. Cohen
    Digestive Diseases and Sciences, 2023, 68 : 1006 - 1015
  • [43] Crohn's Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
    Aggarwal, Manik
    Garg, Rajat
    Parthasarthy, Gopanandan
    Nowacki, Amy S.
    Padival, Ruthvik
    McCullough, Arthur
    Qazi, Taha
    Click, Benjamin
    Rieder, Florian
    Cohen, Benjamin L.
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (03) : 1006 - 1015
  • [44] Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease
    Kwong, Eric K.
    Puri, Puneet
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 6
  • [45] Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease
    Stine, Jonathan G.
    Soriano, Christopher
    Schreibman, Ian
    Rivas, Gloriany
    Hummer, Breianna
    Yoo, Esther
    Schmitz, Kathryn
    Sciamanna, Christopher
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (10) : 3604 - 3611
  • [46] Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries
    Holmer, Magnus
    Melum, Espen
    Isoniemi, Helena
    Ericzon, Bo-Goran
    Castedal, Maria
    Nordin, Arno
    Schultz, Nicolai Aagaard
    Rasmussen, Allan
    Line, Pal-Dag
    Stal, Per
    Bennet, William
    Hagstrom, Hannes
    LIVER INTERNATIONAL, 2018, 38 (11) : 2082 - 2090
  • [47] Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases
    Chang, Yoosoo
    Cho, Juhee
    Cho, Yong Kyun
    Cho, Ara
    Hong, Yun Soo
    Zhao, Di
    Ahn, Jiin
    Sohn, Chong Il
    Shin, Hocheol
    Guallar, Eliseo
    Ryu, Seungho
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (01) : 205 - +
  • [48] The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
    Adams, LA
    Sanderson, S
    Lindor, KD
    Angulo, P
    JOURNAL OF HEPATOLOGY, 2005, 42 (01) : 132 - 138
  • [49] Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease
    Hayashi, Tatsuya
    Saitoh, Satoshi
    Fukuzawa, Kei
    Tsuji, Yoshinori
    Takahashi, Junji
    Kawamura, Yusuke
    Akuta, Norio
    Kobayashi, Masahiro
    Ikeda, Kenji
    Fujii, Takeshi
    Miyati, Tosiaki
    Kumada, Hiromitsu
    GUT AND LIVER, 2017, 11 (05) : 674 - 683
  • [50] The Future of Nonalcoholic Fatty Liver Disease Treatment
    Mazhar, Khurram
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (01) : 57 - +